Ergomed PLC (LON:ERGO) had its target price boosted by investment analysts at Numis Securities Ltd from GBX 280 ($3.69) to GBX 300 ($3.96) in a research note issued to investors on Monday. The brokerage presently has a “buy” rating on the stock. Numis Securities Ltd’s price target points to a potential upside of 38.89% from the stock’s current price.
Ergomed PLC (ERGO) opened at 216.00 on Monday. Ergomed PLC has a 52-week low of GBX 122.50 and a 52-week high of GBX 225.00. The firm’s market cap is GBX 87.55 million. The firm’s 50-day moving average price is GBX 179.50 and its 200 day moving average price is GBX 191.04.
Ergomed PLC (LON:ERGO) last released its earnings results on Monday, September 18th. The company reported GBX 1.20 ($0.02) EPS for the quarter. Ergomed PLC had a return on equity of 2.69% and a net margin of 2.07%. The company had revenue of GBX 2,291 million for the quarter. On average, equities research analysts forecast that Ergomed PLC will post $7.80 EPS for the current year.
TRADEMARK VIOLATION WARNING: “Numis Securities Ltd Increases Ergomed PLC (ERGO) Price Target to GBX 300” was posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/2981921/numis-securities-ltd-increases-ergomed-plc-ergo-price-target-to-gbx-300.html.
Ergomed PLC Company Profile
Ergomed plc is a provider of drug development services to the pharmaceutical industry. The Company operates through two segments: clinical research services (CRS), and drug safety and medical information services (DS&MI). It provides a range of clinical trial planning, management and monitoring services.
Receive News & Ratings for Ergomed PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ergomed PLC and related companies with MarketBeat.com's FREE daily email newsletter.